DeciBio

The requirements of spatial biology tools vary across the R&D value chain, from basic discovery research to scaling the technology for clinical diagnostic applications. Below, we’ve summarized stakeholder feedback on what metrics are prioritized the most during each phase of R&D. Curious to learn more? Check out the Second Edition of our Spatial Biology Market Report: https://lnkd.in/ggvJtwdD #SpatialBiology #SpatialTranscriptomics #SpatialProteomics

Key Themes Across Cell Therapy from ISCT 2024 The ISCT 2024 highlighted innovative manufacturing solutions, exciting technological advancements, and a strong focus on enhancing potency assessments and data-driven processes in cell therapy. Carl Schoellhammer delved into the major takeaways of ISCT by engaging with experts from Ori Biotech, xcellbio, uBriGene Biosciences Inc., and investors at AVANT BIO. Check out their key highlights here: https://lnkd.in/gczGxCSS Were you at the ISCT, International Society for Cell & Gene Therapy Annual Meeting? Share your key takeaways with us! #celltherapy #pharma #ISCT24

Interested in a career in the Life Sciences? Don't miss next month's Nucleate Alumni Summit! Our Vice President of Commercial Megan Nacar will share insights and experiences on how to navigate and thrive in the life sciences field, discussing the diverse career possibilities available to those with life science backgrounds. Whether you're just starting out or looking to pivot, this is a fantastic opportunity to learn and network with the best. There's still time to join us in the Bay Area Scotts Valley on August 27-29! You can grab a ticket here: https://lnkd.in/gyZe84SM #careerdevelopment #lifesciences

Luka Jelcic recently released an updated R&D pipeline overview of AI-first biotech players! Luka's updated overview highlights a net addition of ~50 new programs, with oncology remaining strong and increased activity in neurology and endocrine/metabolic spaces, while autoimmune and cardiovascular programs have slightly decreased. Women's health and dermatology are growing robustly, and several players are developing new diagnostic and disease characterization platforms. For more detailed insights and to stay updated, check out his full LinkedIn post: https://lnkd.in/gASEH2gy Connect with Luka to explore how DeciBio can support your AI-first biotech initiatives and drive innovation together. #Biotech #AI #Innovation *Graphic shows all players who have an active program in a specific stage and therapeutic area.

Agenda Highlight for Day 3 (July 31st) at DxPx U.S. 2024 📅 Join us for an exclusive panel: "Navigating Regulatory Frontiers: Breakthrough Designation and the Impact on Reimbursement," featuring a thought-provoking discussion that will dissect the intersection of regulatory pathways and reimbursement strategies impacting diagnostics companies. Moderator: Angus McQuilken, Industry Relationship Executive – Life Sciences, McDermott Will & Emery Panelists: Paul Gadiock, Partner, McDermott Will & Emery Charles C. Dunham, IV, Shareholder, Greenberg Traurig, LLP Megan Nacar, Vice President of Commercial, DeciBio Check out our full agenda and register today! https://hubs.ly/Q02GXcpR0 #DxPxUS2024 #ADLM2024 #HealthcareInnovation #LifeSciences

Check out the latest insights by Rishikesh Kayathi and Stephane Budel from our latest NGS DxBook report, specifically focusing on the competitive landscape of sample preparation vendors in clinical oncology. Here are some key highlights: Diverse Vendor Utilization: Laboratories offering multiple panels utilize a variety of sample preparation vendors to meet specific needs. This demonstrates the ongoing differentiation among vendors to cater to specific downstream requirements, enabling customers to achieve operational independence. Niche Vendors Excelling: Smaller sample prep vendors are thriving in specialized segments, delivering unique and differentiated products across various panel types, including solid tumors and liquid biopsies. This entrepreneurial spirit is commendable. Market Growth Potential: The sample preparation market is primed for growth. Vendors providing accurate, robust, and cost-effective assays have a significant opportunity for market penetration. Early engagement and integration into lab workflows are crucial for success. Customization Trends: Large-scale providers and academic medical centers frequently use custom solutions ("homebrew") for flexibility, whereas most decentralized labs prefer off-the-shelf kits with minimal customization. Questions? Drop them in the comments! You can schedule a demo of our Dx Books with the link here: https://lnkd.in/eH6MccJw #NGS #OncologyDx #Diagnostics

Spatial Transcriptomics vs. Spatial Proteomics In the latest edition of our Spatial Biology market report we explore both spatial transcriptomics and spatial proteomics revenues and use cases. We want to know what market you think is bigger today. Vote below and drop a line in the comments if you have any questions! You can access a sample of our Spatial Biology market report here: https://lnkd.in/gD5Js_68 #DeciBioMarketPolls

June brought several studies, funding rounds, and legal decisions regarding #LBx.    Company Announcements & Product Launches  BioAI announced a collaboration with Genomic Testing Cooperative (GTC) to enhance patient care in oncology. Goals of the collaboration include data access and AI training, biomarker development, and comprehensive solutions (including tissue and liquid CGP). Natera announced the launch of Prospera Heart with Donor Quantity Score (DQS), which normalizes for the background total cfDNA and results in a more accurate risk assessment, increasing sensitivity from 80.0% to 88.2% and specificity from 76.1% to 84.2%.     Clinical Trials & Study Results  Natera announced DECIPHER, a phase II trial using Signatera to evaluate the efficacy of a HER2-directed ADC in gastroesophageal adenocarcinoma in the adjuvant setting. Patients who are Signatera-positive after neoadjuvant chemo will forgo standard-of-care adjuvant chemo and receive the investigational therapy. Allogene Therapeutics and Foresight Diagnostics announced the initiation of Phase 2 ALPHA3 trial, which is evaluating cema-cel as part of the 1L treatment regimen for newly diagnosed LBCL patients who are likely to relapse following R-CHOP based on the Foresight CLARITY MRD test. NAVERIS announced the publication of a study highlighting the role of NavDx, a Tumor Tissue Modified Viral (TTMV)-HPV DNA blood test, in resolving indeterminate findings during oropharyngeal cancer surveillance with 98% accuracy.     M&A | VC | Private Equity | Legal  Guardant Health has sued Tempus AI, stating that Tempus’ liquid biopsy tests allegedly infringe five patents related to DNA-based cancer testing. Personalis, Inc. has reached a settlement with Foresight Diagnostics, ending its patent infringement lawsuits. Personalis has granted Foresight a non-exclusive, worldwide license to certain patents for WGS-based MRD testing in exchange for tiered royalties on net sales of those tests. Illumina completed the divestiture of GRAIL, which is now a public and independent company, though Illumina will maintain a minority share of 14.5% in the company. BillionToOne raised $130M in Series D funding, aiming to expand diagnostics options via their Northstar Select and Response and their UNITY Fetal Risk Screen tests. Rarity Bioscience closed $7M funding round which will be used to advance their mission to democratize nucleic acid mutation detection.    Read the newsletter for more:  https://lnkd.in/gYdJvPRn Check out our new Oncology Liquid Biopsy Market Report 2024 - 2029: https://lnkd.in/gh7XPQ3p   Sign up to receive our Liquid Biopsy Newsletter in your email: https://lnkd.in/gKQn7_zp   The headlines have been handcrafted by Amal Thommil, Graham F., Nila Venkat, and Antony Awad     #earlydetection #productlaunches #cancermonitoring #liquidbiopsytesting 

In our latest Q&A session featuring Dr. Michael Torres, CEO of CrossBridge Bio, we delve into the advancements and challenges in the field of Antibody-Drug Conjugates (ADCs) and the evolving biotech ecosystem in Texas. Don't miss out on this expert perspective! Read the full interview here: https://lnkd.in/g_M2_yh4 Interviewed by: Joe Daccache, Ph.D. and Graham F. #Biotech #Pharma #ADCs

We are thrilled to announce the launch of the Third Edition of our Oncology Liquid Biopsy market report, which states that the global oncology liquid biopsy market is predicted to reach $10.1B by 2029. There have been numerous technological, clinical, and commercial updates since the last report was published in 2022 and we took a completely updated look at the LBx landscape, informed by >200 interviews and survey responses across oncologists, pathologists, and pharma. Learn more about DeciBio’s Oncology Liquid Biopsy Market Report – Third Edition: 2024-2029 and download a sample of the report here: https://lnkd.in/gh7XPQ3p #liquidbiopsy #therapyselection #MRD #monitoring #earlycancerdetection #precisiononcology